Page last updated: 2024-12-06

icotidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Icotidine is a synthetic nicotinic acetylcholine receptor agonist that is a derivative of nicotine. It is structurally similar to nicotine, but with a modified pyridine ring. Icotidine has been shown to have a variety of effects, including stimulating the release of dopamine in the brain. This makes it a potential treatment for neurodegenerative diseases such as Parkinson's disease. Icotidine is also being investigated for its potential to improve cognitive function in patients with Alzheimer's disease. The importance of Icotidine lies in its unique pharmacological properties and its potential for treating a variety of neurodegenerative diseases. It is studied because of its potential therapeutic applications and to understand its mechanisms of action on the brain. However, it is important to note that Icotidine is not currently approved for use in humans.'

icotidine: structure given in first source; RN given refers to tri-HCl [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72108
CHEMBL ID145087
CHEBI ID177603
SCHEMBL ID144915
SCHEMBL ID10972956
MeSH IDM0127913

Synonyms (22)

Synonym
CHEBI:177603
2-[4-(3-methoxypyridin-2-yl)butylamino]-5-[(6-methylpyridin-3-yl)methyl]-1h-pyrimidin-6-one
sk&f-93319
71351-79-6
icotidine (usan)
D04494
icotidine
CHEMBL145087
sk&f 93319
icotidine [usan]
25y9g9575k ,
2-((4-(3-methoxy-2-pyridyl)butyl)amino)-5-((6-methyl-3-pyridyl)methyl)-4(1h)-pyrimidinone
unii-25y9g9575k
4(1h)-pyrimidinone, 2-((4-(3-methoxy-2-pyridinyl)butyl)amino)-5-((6-methyl-3-pyridinyl)methyl)-
2-[[4-(3-methoxy-2-pyridyl)butyl]amino]-5-[(6-methyl-3-pyridyl)methyl]-4(1h)-pyrimidinone
SCHEMBL144915
2-[[4-(3-methoxy-2-pyridyl)butyl]amino]-5-[(6-methyl-3-pyridyl)methyl]-4-(1h)-pyrimidinone
GJCSPRIRQYWXRW-UHFFFAOYSA-N
DTXSID40221555
SCHEMBL10972956
2-((4-(3-methoxypyridin-2-yl)butyl)amino)-5-((6-methylpyridin-3-yl)methyl)pyrimidin-4(3h)-one
Q27254011

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Bioavailability is reduced at higher dose levels."( The pharmacokinetics in man of SK&F 93319--a new antagonist of histamine H1 and H2 receptors.
Burland, WL; Doyle, E; Griffiths, R; Johnson, P; Lee, RM; McDowall, RD; Taylor, DC, 1984
)
0.27

Dosage Studied

ExcerptRelevanceReference
" SK&F 93319, 8 X 10(-8) and 4 X 10(-7) mol kg-1 min-1 antagonized depressor responses to injections of histamine and the maximum displacement of histamine dose-response curves exceeded that which can be obtained with either an H1-receptor antagonist or an H2-receptor antagonist alone."( Cardiovascular studies with SK&F 93319, an antagonist of histamine at both H1- and H2-receptors.
Harvey, CA; Owen, DA, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID23735Logarithm of partition coefficient of the neutral form of compound given for octanol/water solvent system1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID19257Logarithm of partition coefficient of the neutral form of compound given for chloroform/water solvent system1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID24179logBB, log(C brain/C blood)1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Computation of brain-blood partitioning of organic solutes via free energy calculations.
AID16331Delta logPoct-cyc1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's2 (40.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]